Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Biomark DiagnosticsSTU:20B 29 EV-to-EBITDA is -50.58 as of Sep. 02, 2026. GuruFocus rates STU:20B with a GF Score™ of 29/100. The stock has 3 warning signs investors should review. Among 121 Medical Diagnostics & Research companies, Biomark Diagnostics ranks worse than 826445.45% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Biomark Diagnostics's enterprise value is €32.57 Mil.
Biomark Diagnostics's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was €-0.64 Mil. Therefore, Biomark Diagnostics's EV-to-EBITDA for today is -50.58.
The historical rank and industry rank for Biomark Diagnostics's EV-to-EBITDA or its related term are showing as below:
STU:20B'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -50.8 Med: -16.13 Max: -6.04
Current: -50.8
During the past 13 years, the highest EV-to-EBITDA of Biomark Diagnostics was -6.04. The lowest was -50.80. And the median was -16.13.
STU:20B's EV-to-EBITDA is ranked worse than 100% of 121
companies
in the Medical Diagnostics & Research industry
Industry Median: 16.33
vs STU:20B: -50.80
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Biomark Diagnostics's PE Ratio (TTM) for today is calculated as:
Biomark Diagnostics's share price for today is €0.288.
Biomark Diagnostics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.018.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Biomark Diagnostics's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:20B vs TMO, DHR, NTRA: EV-to-EBITDA Comparison
For the Diagnostics & Research subindustry, Biomark Diagnostics's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Biomark Diagnostics EV-to-EBITDA vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Biomark Diagnostics's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Biomark Diagnostics's EV-to-EBITDA falls into.
Biomark Diagnostics's current Enterprise Value is €32.57 Mil.
Biomark Diagnostics's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.64 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Biomark Diagnostics (STU:20B) has a EV-to-EBITDA of -50.58 as of Sep. 02, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Biomark Diagnostics. According to the industry distribution chart, Biomark Diagnostics ranks #999999 out of 121 companies in the Medical Diagnostics & Research industry.
Is Biomark Diagnostics' EV-to-EBITDA too high?
Biomark Diagnostics' current EV-to-EBITDA is -50.58. Based on the distribution chart, Biomark Diagnostics ranks #999999 out of 121 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, Biomark Diagnostics has a GF Score™ of 29/100, reflecting its overall financial health beyond just this single metric.
How does Biomark Diagnostics' EV-to-EBITDA compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Biomark Diagnostics ranks #999999 out of 121 companies for EV-to-EBITDA. This places Biomark Diagnostics in the lower half of its industry. The industry median EV-to-EBITDA is 16.33. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Medical Diagnostics & Research company?
The median EV-to-EBITDA among Medical Diagnostics & Research companies is 16.33, based on 121 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Biomark Diagnostics. For the Medical Diagnostics & Research industry, the median EV-to-EBITDA is 16.33 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Biomark Diagnostics's current EV-to-EBITDA is -50.58. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biomark Diagnostics stock overvalued right now?
Biomark Diagnostics (STU:20B) has a current EV-to-EBITDA of -50.58. The current EV-to-EBITDA is -50.58. Biomark Diagnostics' overall GF Score™ is 29/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Biomark Diagnostics (STU:20B), the current EV-to-EBITDA is -50.58 as of Sep. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Biomark Diagnostics Inc is a Canada-based oncology-focused company. It is engaged in the development of the early-stage cancer diagnostic technology platform. The company develops non-invasive cancer diagnostic solutions which will help to detect, monitor, and assess early cancer treatment. Its research and development are focused on the role that metabolomics plays in early cancer detection. The company's objective is to commercialize its inventive technology. and strive to increase the predictive accuracy in early-stage cancer detection.
29GF Score
Get the complete analysis for STU:20B
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:20B has been successfully added to your 
